Preface

doi:10.1016/j.iac.2008.08.002

Immunology and Allergy Clinics of North America

Volume 28, Issue 4, November 2008, Pages xv-xvi

https://doi.org/10.1016/j.iac.2008.08.002 Get rights and content

Section snippets

Dedication

This issue is dedicated to an exceptional leader, Dr. Fred Rosen, who, through ingenuity and extraordinary dedication, elevated the field of primary immunodeficiency to its current stature for the benefit of patients.

References (0)

Cited by (4)

Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America
2014, Allergologia et Immunopathologia
Citation Excerpt :
To minimise immune complex formation, proper reconstitution of these products with adequate diluent requires particular attention to factors such as temperature. It has also been noted that frequent switching of products for immunoglobulin reconstitution71–73 and rapid infusion both increase the risk for AEs. Adverse events may also be related to variations in the properties of different IVIG preparations, including sugar content—particularly sucrose—hyperosmolarity, and IgA (Table 3).
Antibodies are an essential component of the adaptative immune response and hold long-term memory of the immunological experiences throughout life. Antibody defects represent approximately half of the well-known primary immunodeficiencies requiring immunoglobulin replacement therapy. In this article, the authors review the current indications and therapeutic protocols in the Latin American environment. Immunoglobulin replacement therapy has been a safe procedure that induces dramatic positive changes in the clinical outcome of patients who carry antibody defects.
Safety and Efficacy of Hizentra® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies
2023, Journal of Clinical Immunology
Safety and Efficacy of Hizentra ® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies
2022, Research Square
Neonatal Formulary 6: Drug Use in Pregnancy and the First Year of Life
2011, Neonatal Formulary 6: Drug Use in Pregnancy and the First Year of Life

View full text